ISCO3 Recommendation based on the preliminary results about the use of O_2/O_3 in the treatment /prevention of Novel Coronavirus Pneumonia (COVID-19).

Security alert: MAH volume > 100 mL // Risk of thrombus in COVID-19 + Patients

The up-date of these recommendations take into consideration the preliminary results listed in "ISCO3 follow-up of the original paper with outcomes".

ISCO3 Theoretical protocol for Intervention in case of Mild /Moderate /Severe **COVID-19 +** **CRITICAL** O_2/O_3 NON-considering	**O_3SS 5 →3 µg/mL (bub.) 250 mL, Daily x 10 d** Or MAH Blood vol. 100 mL. Only in patients with normal d dimer values O_2/O_3: Blood 1:1. Daily for 5 days + 3 weekly x 10/14 days. Firs week 30 µg/mL, last 45 µg/mL or EBOO (not yet outcome)	Consider glutathione 1.2 g or / and Vitamin C 1-3 g in 100 mL of saline. Two times a week for 4 weeks Prelim. Dada Indicate ↑ success of O_3SS
Intervention alternative when O_3SS or MAH are not available **RIO$_3$: 1 every 12 h for 14 days**	RIO3 / Conc. / Vol. / Dose (mg): Day 1 / 2: 20 / 100 / 2; Day 3 / 4: 25 / 150 / 3.75; Day 5 / 6: 30 / 150 / 4.5; Day 7 / 8: 35 / 200 / 7; Day 8-14: 40 / 200 / 8 **+ MiAH** 5 mL Blood + 5 mL O_3 90 µg/mL, Once a week for 4 weeks.	**Support:** *Archiv of Medical Research* 2005. 36 (5):549–54 // Virulence 1(3), 2010: 215-217. // *Ozone: Science & Egineering* 2012.34: 451-458 //*Ozone: Science & Engineering*, 2016 38 (322-345). **Oral Therapy**: Probiotic plus supplementation proposed in Prevention protocol ↓
ISCO3 Theoretical protocol for Prevention Medical doctor or occupational risk people	**MiAH** 5 mL Blood + session 1/2: 5 mL O_3 25 µg/mL; session 3/4: 5 mL O_3 30 µg/mL; session 5/6: 5 mL O_3 30 µg/mL. Once a week. Or **Rectal insufflation** 3 times a week 40 µg/mL /100 mL	Consider: glutathione 600 mg or / and Vit. C 1 g in 100 mL of saline i.v. once a week. **Oral:** Once a day: N-acetyl cysteine 600 mg for 30 days, plus Vit.D 2000 UI (o 50 µg). Twice a day Vit. C 500 mg. Melatonin 3/5 mg 30 min before sleep.
ISCO3 Theoretical protocol for Recovery	**Rectal insufflation** 2 times a week 30 µg/mL /100 mL, to complete 20 session, then 2 months off. Repeat treatment cycles until complete remission	**Oral:** Once a day: N-acetyl cysteine 600 mg 30 days off / 30 days on, plus Vit.D 2000 UI (o 50 µg). Twice a day Vit. C 300 mg, Zn 5 mg. Melatonin 3/5 mg 30 min before sleep.
Personal Protective Equipment Disinfection	**O_3 concentration** >15 µg/mL **Contact time:** >10 min **Humidity:** 99 %	**Ref:** Antioxidants 2020, 9, 1222; doi:10.3390/antiox9121222

Ozone in Personal Protective Equipment Disinfection

Bernardino Clavo, Elizabeth Córdoba-Lanús, Francisco Rodríguez-Esparragón, Sara E. Cazorla-Rivero, Omar García-Pérez, José E. Piñero, Jesús Villar, Ángeles Blanco, Cristina Torres-Ascensión, José L. Martín-Barrasa, Jesús M. González-Martin, Pedro Serrano-Aguilar and Jacob Lorenzo-Morales. Effects of Ozone Treatment on Personal Protective Equipment Contaminated with SARS-CoV-2. Antioxidants 2020, 9, 1222; doi:10.3390/antiox9121222

Angeles Blanco, Francisco de Borja Ojembarrena, Bernardino Clavo, Carlos Negro. Ozone potential to fight against SAR-COV-2 pandemic: facts and research needs. 2021 Jan 2;1-15. Environ Sci Pollut Res Int doi: 10.1007/s11356-020-12036-9.

Ozone in Environments Disinfection

F De Caro, G Moccia, A Borrelli, A Annecchiarico, G Cioffi, A Campanella, O Motta, V Caputo, G Boccia, and M Capunzo. SARS-CoV-2: Sanitize a hospital Eur J Public Health. 2020 Sep; 30(Suppl 5): ckaa166.716. doi: 10.1093/eurpub/ckaa166.716

Zucker, Ines; Lester, Yaal; Alter, Joel; Werbner, Michal; Yecheskel, Yinon; Gal-Tanamy, Meital; Dessau, Moshe. Pseudoviruses for the assessment of coronavirus disinfection by ozone. ***Environ Chem Lett; 1-7, 2021 Jan 13.***

Reference:

Bocci V. *et al.* (2010) Ozonation of human HIV-infected plasmas for producing a global vaccine: How HIV-patients may help fight the HIV pandemia. Virulence 1(3) 215-217.

Hernández Rosales *et al*. (2005) Ozone therapy effects on biomarkers and lung function in asthma. *Archiv of Medical Research* 36 (5):549–54

Jeffrey I Mechanick *et al*. Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Nutrition Taskforce JPEN J Parenter Enteral Nutr. 2020 Oct 23. doi: 10.1002/jpen.2036. Online ahead of print.

Mawsouf M.N *et al*. Ozone Therapy in Patients with Viral Hepatitis C. Ten Years of Experience (2012). *Ozone: Science & Egineering* 34: 451-458

Viebahn-Hänsler *et al*. (2016). Ozone in Medicine: Clinical Evaluation and Evidence Classification of the Systemic Ozone Applications, Major Autohemotherapy and Rectal Insufflation, According to the Requirements for Evidence-Based Medicin. *Ozone: Science & Engineering*, 38 (322-345).

Preprint / Preliminary

Fedorova T.A., Bakuridze E.M., Yesayan R.M., Kozachenko I.F., Nikolaeva A.V. Application of ozone therapy in the complex treatment of patients with COVID-19 (Preliminary results). FSBI NMITs AGP named after V.I. Kulakov "Ministry of Health of Russia, Moscow. [Ozone therapy SSO3 was given to 134 patients (patients' age - from 18 to 94 years).

Sharma A, Shah M, Satya Lakshmi, Sane H, Captain J, Gokulchandran N, Khubchandani P, Pradeep. M.K, Gote P, Tuppekar B, Kulkarni P, Paranjape A, Pradhan R, Varghese R, Kasekar S, Nair V, Khanbande. A Pilot study for treatment of COVID-19 patients in moderate stage using Intravenous administration of Ozonized saline as an adjuvant treatment- Registered Clinical Trial. *Journal of Biological Regulators & Homeostatic Agents*. Submitted

Please, refer any up-date / side effect by E.mail: info@isco3.org